Memuna Rashid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Memuna Rashid has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Andre Lopes
Cancer Research UK and Cancer Trials Centre University College London London UK
4 shared publications - Malena Daich Varela
University College London Institute of Ophthalmology, London, UK
2 shared publications - Michel Michaelides
UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK
2 shared publications Aiman Haider
Department of Cellular Pathology, University College London Hospital, London, United Kingdom
1 shared publicationAlex Freeman
Department of Cellular Pathology, University College London Hospital, London, United Kingdom
1 shared publicationAndre Lopes
Cancer Research UK & UCL Cancer Trials Centre, London, UK
1 shared publication
Latest Publications
- Open Access
- 25 February 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (5) , 101791
Pattern of progression and post-progression survival following transarterial embolisation: An analysis of the TACE-2 and TACTICS trials
- 25 February 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (5) , 101791
Open AccessPattern of progression and post-progression survival following transarterial embolisation: An analysis of the TACE-2 and TACTICS trials
- Open Access
- 2 December 2025
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (3) , 101026
Assessing Agreement between Blue-Light and Green-Light Autofluorescence of Macular Hyperautofluorescent Rings in Inherited Retinal Diseases
- 2 December 2025
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (3) , 101026
Open AccessAssessing Agreement between Blue-Light and Green-Light Autofluorescence of Macular Hyperautofluorescent Rings in Inherited Retinal Diseases
- Open Access
- 4 October 2025
- Published by SAGE Publications in Clinical Trials
- Vol. 22 (6) , 676-686
Estimating treatment effects in trials with outcome data truncated by death: A case study on aligning estimators with estimands
Background/Aims: Randomised clinical trials assessing treatment effects on health outcomes (e.g. quality of life) can be affected by data truncation by death, where some patients die before their outcome measure is assessed and their data become undefined after death. The ICH E9(R1) addendum on estimands discusses four strategies for handling such terminal intercurrent events: hypothetical, composite, while-alive, and principal stratum. While the addendum emphasises the importance of aligning statistical methods of analysis (i.e. estimators) with estimands, it does not provide specific guidance and consideration on the choice of estimators in practice. We aim to (1) demonstrate how some statistical methods commonly used in trials can be used to estimate different intercurrent event strategies for handling data truncation by death; and (2) describe how missing outcome data (e.g. due to missed assessments or loss to follow-up) can be handled for each estimator. Method: We use data from SCORAD, a non-inferiority randomised trial comparing single-fraction versus multifraction radiotherapy on ambulatory status at 8 weeks (primary outcome) among patients with spinal canal compression from metastatic cancer. Here, we estimate the effect of radiotherapy on quality of life (secondary outcome), quantified by the difference in mean global health status between the two groups at 8 weeks. We outline the strategies for handling death and describe a selection of commonly used estimators corresponding to each strategy. The handling of missing data is considered and demonstrated as part of the estimation process. Results: The hypothetical strategy, targeting a treatment effect assuming patients had not died, can be estimated using linear mixed models (a likelihood approach) or multiple imputation (a method commonly used for handling missing data). The composite and while-alive strategies relate to the ‘outcome’ attribute of the estimand; the former incorporates death into the definition of the primary outcome, the latter only uses outcome data before death. These can be estimated by re-defining the outcome, for example, assigning a value reflecting poor global health status post-death, or using the last global health status observed before death. The principal stratum strategy, targeting a treatment effect among patients who would not die under either treatment, can be estimated by an analysis of survivors under specific assumptions. Missing data can be handled with linear mixed models or multiple imputation. Conclusions: Regarding death as an intercurrent event in the process of defining the estimand for the trial will help clarify the choice of suitable estimators. When choosing the estimators, it is important to consider the assumptions required by the estimators as well as their plausibility given the setting of the trial.
- 4 October 2025
- Published by SAGE Publications in Clinical Trials
- Vol. 22 (6) , 676-686
Open AccessEstimating treatment effects in trials with outcome data truncated by death: A case study on aligning estimators with estimands
Background/Aims: Randomised clinical trials assessing treatment effects on health outcomes (e.g. quality of life) can be affected by data truncation by death, where some patients die before their outcome measure is assessed and their data become undefined after death. The ICH E9(R1) addendum on estimands discusses four strategies for handling such terminal intercurrent events: hypothetical, composite, while-alive, and principal stratum. While the addendum emphasises the importance of aligning statistical methods of analysis (i.e. estimators) with estimands, it does not provide specific guidance and consideration on the choice of estimators in practice. We aim to (1) demonstrate how some statistical methods commonly used in trials can be used to estimate different intercurrent event strategies for handling data truncation by death; and (2) describe how missing outcome data (e.g. due to missed assessments or loss to follow-up) can be handled for each estimator. Method: We use data from SCORAD, a non-inferiority randomised trial comparing single-fraction versus multifraction radiotherapy on ambulatory status at 8 weeks (primary outcome) among patients with spinal canal compression from metastatic cancer. Here, we estimate the effect of radiotherapy on quality of life (secondary outcome), quantified by the difference in mean global health status between the two groups at 8 weeks. We outline the strategies for handling death and describe a selection of commonly used estimators corresponding to each strategy. The handling of missing data is considered and demonstrated as part of the estimation process. Results: The hypothetical strategy, targeting a treatment effect assuming patients had not died, can be estimated using linear mixed models (a likelihood approach) or multiple imputation (a method commonly used for handling missing data). The composite and while-alive strategies relate to the ‘outcome’ attribute of the estimand; the former incorporates death into the definition of the primary outcome, the latter only uses outcome data before death. These can be estimated by re-defining the outcome, for example, assigning a value reflecting poor global health status post-death, or using the last global health status observed before death. The principal stratum strategy, targeting a treatment effect among patients who would not die under either treatment, can be estimated by an analysis of survivors under specific assumptions. Missing data can be handled with linear mixed models or multiple imputation. Conclusions: Regarding death as an intercurrent event in the process of defining the estimand for the trial will help clarify the choice of suitable estimators. When choosing the estimators, it is important to consider the assumptions required by the estimators as well as their plausibility given the setting of the trial.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (28) , 3070-3080
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study
PURPOSE: Efficacy of immune checkpoint inhibitors in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) is limited. The NEPTUNES study evaluated combination nivolumab and ipilimumab in patients with immunogenic signature–positive (ImS+) mCRPC. MATERIALS AND METHODS: This open-label, 2-cohort, phase II trial enrolled patients with ImS+ mCRPC progressing on ≥1 previous line of treatment. ImS+ was defined by (1) mismatch repair deficiency (MMRD); (2) DNA damage repair gene loss; and/or (3) high inflammatory infiltrate (HII). Patients received four doses of nivolumab 1 mg/kg + ipilimumab 3 mg/kg (C1) or nivolumab 3 mg/kg + ipilimumab 1 mg/kg (C2) followed by nivolumab 480 mg once every 4 weeks up to 10 cycles. The primary end point was composite response rate (CRR) assessed radiologically, biochemically, and by reduction of circulating tumor cells. Secondary end points included toxicity, progression-free survival, overall survival, and duration of response. RESULTS: Between May 2018 and June 2022, 35 (C1) and 36 (C2) patients commenced treatment. The CRR in C1 was 14/35 (40%, 90% CI, 26% to 55%) and in C2 was 9/36 (25%, 90% CI, 14% to 40%). The overall CRR was 23/71 (32%, 90% CI, 23% to 43%). Response rates were higher in patients with MMRD (7/10), BRCA2 loss (4/8), and HII ± other ImS+ features (13/30). Duration of response for patients with HII without other ImS+ features, DNA repair gene loss without MMRD, and MMRD was 2.6, 17.3, and 10 months, respectively. Grade 3 to 4 treatment-related adverse events occurred in 22/35 (63%) in C1 and 12/36 (33%) patients in C2. There were no treatment-related deaths. CONCLUSION: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg is an active treatment in ImS+ pretreated mCRPC. Nivolumab 3 mg/kg + ipilimumab 1 mg/kg has less toxicity but may have lower efficacy. HII is a promising prospectively tested predictive biomarker in prostate cancer that could be integrated into future trials.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (28) , 3070-3080
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study
PURPOSE: Efficacy of immune checkpoint inhibitors in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) is limited. The NEPTUNES study evaluated combination nivolumab and ipilimumab in patients with immunogenic signature–positive (ImS+) mCRPC. MATERIALS AND METHODS: This open-label, 2-cohort, phase II trial enrolled patients with ImS+ mCRPC progressing on ≥1 previous line of treatment. ImS+ was defined by (1) mismatch repair deficiency (MMRD); (2) DNA damage repair gene loss; and/or (3) high inflammatory infiltrate (HII). Patients received four doses of nivolumab 1 mg/kg + ipilimumab 3 mg/kg (C1) or nivolumab 3 mg/kg + ipilimumab 1 mg/kg (C2) followed by nivolumab 480 mg once every 4 weeks up to 10 cycles. The primary end point was composite response rate (CRR) assessed radiologically, biochemically, and by reduction of circulating tumor cells. Secondary end points included toxicity, progression-free survival, overall survival, and duration of response. RESULTS: Between May 2018 and June 2022, 35 (C1) and 36 (C2) patients commenced treatment. The CRR in C1 was 14/35 (40%, 90% CI, 26% to 55%) and in C2 was 9/36 (25%, 90% CI, 14% to 40%). The overall CRR was 23/71 (32%, 90% CI, 23% to 43%). Response rates were higher in patients with MMRD (7/10), BRCA2 loss (4/8), and HII ± other ImS+ features (13/30). Duration of response for patients with HII without other ImS+ features, DNA repair gene loss without MMRD, and MMRD was 2.6, 17.3, and 10 months, respectively. Grade 3 to 4 treatment-related adverse events occurred in 22/35 (63%) in C1 and 12/36 (33%) patients in C2. There were no treatment-related deaths. CONCLUSION: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg is an active treatment in ImS+ pretreated mCRPC. Nivolumab 3 mg/kg + ipilimumab 1 mg/kg has less toxicity but may have lower efficacy. HII is a promising prospectively tested predictive biomarker in prostate cancer that could be integrated into future trials.
- Open Access
- 28 November 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 271, 243-249
The Effects of Pregnancy on Disease Progression of Retinitis Pigmentosa
- 28 November 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 271, 243-249
Open AccessThe Effects of Pregnancy on Disease Progression of Retinitis Pigmentosa